Yisheng Biopharma of Beijing was cleared to start China trials of its PIKA-based immunotherapy to treat solid tumors. YS-ON-001 is a first-in-class immunomodulating product designed to promote both innate and adaptive immune responses through the TLR3, RIG-I and MDA5 pathways. The US FDA has granted US Orphan Drug Designation to YS-ON-001 for pancreatic cancer and hepatocellular carcinoma. The PIKA technology is already being tested in two other Yisheng candidates: vaccines for hepatitis B and rabies. Currently in a China Phase III trial, the rabies vaccine is Yisheng’s lead product.
Source: China Biotoday
